Dihydroergotamine Nasal Spray

Major

Dihydroergotamine Nasal Spray Diltiazem Cardizem Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Dronedarone Multaq Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Duvelisib Copiktra Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Dihydroergotamine Nasal Spray Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Nasal Spray Enzalutamide Xtandi Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Dihydroergotamine Nasal Spray Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Dihydroergotamine Nasal Spray Fexinidazole An increased CYP3A4 substrate exposure Details Dihydroergotamine Nasal Spray Fluconazole Diflucan Increased plasma concentrations of ergot derivatives and increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Fluoxetine RECONCILE Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Fluvoxamine Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Fosnetupitant Increased exposure of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Gepotidacin Blujepa Increased CYP3A4 substrate with NTI exposure Details Dihydroergotamine Nasal Spray Imatinib Gleevec Increased dihydroergotamine plasma concentrations and an increased risk of ergotism Details Dihydroergotamine Nasal Spray Isavuconazole Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Isavuconazonium Cresemba Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Ivacaftor Kalydeco Increased CYP3A substrate exposure Details Dihydroergotamine Nasal Spray Lanreotide Altered exposure to CYP3A4 substrate Details Dihydroergotamine Nasal Spray Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Dihydroergotamine Nasal Spray Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Dihydroergotamine Nasal Spray Lenacapavir Sunlenca Increased dihydroergotamine exposure Details Dihydroergotamine Nasal Spray Lorlatinib Lorbrena Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Dihydroergotamine Nasal Spray Lumacaftor Reduced exposure to CYP3A substrate Details Dihydroergotamine Nasal Spray Mavorixafor Xolremdi Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Dihydroergotamine Nasal Spray Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Dihydroergotamine Nasal Spray Mitotane Lysodren Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Dihydroergotamine Nasal Spray Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Dihydroergotamine Nasal Spray Netupitant Increased exposure of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Nilotinib Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Dihydroergotamine Nasal Spray Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Dihydroergotamine Nasal Spray Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Dihydroergotamine Nasal Spray Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Dihydroergotamine Nasal Spray Pazopanib Votrient Increased dihydroergotamine concentrations and risk of ergot toxicity Details Dihydroergotamine Nasal Spray Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Nasal Spray Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Dihydroergotamine Nasal Spray Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Nasal Spray Propatyl Nitrate Increased risk of ergotism Details Dihydroergotamine Nasal Spray Propranolol Hemangeol Increased risk of coronary artery vasospasm Details